International Journal of STD & AIDS > Volume 18, Number 9 > Pp. 630-632

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gupta, R K Articles by Orkin, C. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Original research articles

Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice

R K Gupta, Clive Loveday, U Kalidindi, M Lechelt, Celia Skinner and Chloe Orkin

Barts and The London NHS Trust, London, UK; Barts and The London NHS Trust, London, UK; Barts and The London NHS Trust, London, UK; Barts and The London NHS Trust, London, UK; Barts and The London NHS Trust, London, UK; Barts and The London NHS Trust, London, UK

Escalating drug resistance in treatment-experienced HIV-1-infected patients has made management increasingly difficult. In clinical trials, tipranavir (TPV) has produced potent and durable responses in such patients, although experience in clinical cohorts is limited. A retrospective clinical case review was undertaken of triple-class experienced HIV-1-infected patients receiving optimized boosted TPV-containing regimens and T20 with up to 108 weeks follow-up. Antiretroviral therapy (ART) resistance profiles were characterized using International Aids Society (IAS)-USA scoring and 'TPV resistance score' (TPV-RS) at baseline and failure. Five of 12 patients had undetectable virus (<50 copies/mL) after median 84 weeks (range 60–108), and 1/12 < had 700 copies/mL after 40 weeks. Six of 12 patients failed after 36 (range 12–48) weeks and were more likely to have 3 TPV-RS mutations than non-failures (P = 0.06). Presence of a major IAS-USA mutation at baseline was strongly associated with absence of a 1 log viral load drop at 24 weeks (P = 0.02). TPV-containing regimens showed impressive efficacy and tolerability in this heavily experienced cohort.

Key Words: HIV-1 • TREATMENT-EXPERIENCED • DRUG RESISTANCE • TIPRANAVIR • GENOTYPE • SCORE

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?